Linsitinib has been tested in combination with erlotinib in patients with NSCLC with EGFR-activating mutations and resulted in inferior outcomes compared to erlotinib alone in a phase II study [241]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.